0001354457-24-000299.txt : 20240425
0001354457-24-000299.hdr.sgml : 20240425
20240425090921
ACCESSION NUMBER: 0001354457-24-000299
CONFORMED SUBMISSION TYPE: 25-NSE
CONFIRMING COPY:
PUBLIC DOCUMENT COUNT: 2
FILED AS OF DATE: 20240425
DATE AS OF CHANGE: 20240425
SUBJECT COMPANY:
COMPANY DATA:
COMPANY CONFORMED NAME: Panbela Therapeutics, Inc.
CENTRAL INDEX KEY: 0001029125
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 870543922
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 25-NSE
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39468
BUSINESS ADDRESS:
STREET 1: 712 VISTA BLVD #305
CITY: WACONIA
STATE: MN
ZIP: 55387
BUSINESS PHONE: 9524791196
MAIL ADDRESS:
STREET 1: 712 VISTA BLVD #305
CITY: WACONIA
STATE: MN
ZIP: 55387
FORMER COMPANY:
FORMER CONFORMED NAME: Sun BioPharma, Inc.
DATE OF NAME CHANGE: 20150911
FORMER COMPANY:
FORMER CONFORMED NAME: Cimarron Medical, Inc.
DATE OF NAME CHANGE: 20150602
FORMER COMPANY:
FORMER CONFORMED NAME: CIMARRON SOFTWARE INC
DATE OF NAME CHANGE: 19961217
FILED BY:
COMPANY DATA:
COMPANY CONFORMED NAME: Nasdaq Stock Market LLC
CENTRAL INDEX KEY: 0001354457
ORGANIZATION NAME:
IRS NUMBER: 521165937
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 25-NSE
BUSINESS ADDRESS:
STREET 1: One Liberty Plaza
CITY: New York
STATE: NY
ZIP: 10006
BUSINESS PHONE: 301-978-4144
MAIL ADDRESS:
STREET 1: Office of General Counsel
STREET 2: 805 King Farm Blvd.
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
FORMER COMPANY:
FORMER CONFORMED NAME: The Nasdaq Stock Market LLC
DATE OF NAME CHANGE: 20060224
25-NSE
1
primary_doc.xml
X0203
0001354457
Nasdaq Stock Market LLC
0001029125
Panbela Therapeutics, Inc.
001-39468
712 Vista Blvd, #305
Waconia
MN
MINNESOTA
55387
612-963-3559
Common stock
17 CFR 240.12d2-2(b)
Aravind Menon
Hearings Advisor
2024-04-25
EX-99.25
2
pbladelistreason.txt
Delisting Determination, The Nasdaq Stock Market, LLC, April 25, 2024,
Panbela Therapeutics, Inc.
The Nasdaq Stock Market LLC (the Exchange) has determined to remove
from listing the securities of Panbela Therapeutics, Inc.,
effective at the opening of the trading session on May 6, 2024.
Based on review of information provided by the Company, Nasdaq Staff
determined that the Company no longer qualified for listing on the
Exchange pursuant to Listing Rules 5550(a)(2) and 5550(b)(1).
The Company was notified of the Staff determination on November 28,
2023. The Company requested a hearing on December 5, 2023.
On January 22, 2024, the Company received an additional delist
determination letter for its failure to meet the requirement in
Listing Rule 5550(a)(4).
On March 5, 2024, upon review of the information provided by the
Company, the Panel determined to deny the Company request to remain
listed on the Exchange.
On March 6, 2024, the Company submitted a request for reconsideration
to the Panel pursuant to Listing Rule 5815(d)(5)
The Company securities were suspended on March 7, 2024.
On March 15, 2024, the Panel denied the Company request for a
reconsideration.
The Company did not appeal the amended Decision to the Nasdaq Listing
and Hearing Review Council (Council) and the Council did not call
the matter for review. The Staff determination to delist the Company
became final on April 19, 2024.